More than a decade into coordinated federal litigation over Johnson & Johnson’s talcum powder products and alleged links to ovarian cancer, a New Jersey magistrate judge has ordered plaintiffs to confront a foundational evidentiary problem: whether they can present admissible expert testimony on specific causation. In a ruling issued in the U.S. District Court for the District of New Jersey, the court directed plaintiffs in the talc MDL to show cause why their cases should not be dismissed with prejudice for failing to identify admissible expert opinions tying talc exposure to an individual claimant’s ovarian cancer. The order places renewed attention on the reliability demands of differential etiology and the practical consequences of expert withdrawals in mass tort proceedings.
Judge Singh Orders Plaintiffs to Show Cause on Specific Causation
U.S. Magistrate Judge Rukhsanah L. Singh granted Johnson & Johnson’s motion for an order to show cause and instructed plaintiffs to explain why more than 69,000 cases in the multidistrict litigation should not be dismissed with prejudice for failure to point to admissible expert opinion on specific causation. The order emphasizes that, notwithstanding generalized evidence about potential associations, plaintiffs must still establish that talc use was a substantial contributing factor in each claimant’s disease. Judge Singh identified multiple reasons for “grave doubt” that any given plaintiff in the MDL could satisfy that burden with reliable, admissible testimony under the applicable evidentiary framework.
The order also reflects the court’s effort to manage an MDL of unusual size while addressing merits-based concerns in a procedurally efficient way. Judge Singh noted that individualized motion practice by tens of thousands of plaintiffs to resolve the same core issue would be impractical. Instead, the show cause process is intended to create an orderly mechanism for the parties to be heard and for the court to determine which claims, if any, can proceed in light of the contested state of the admissible science on specific causation. Plaintiffs were given 120 days to respond, and Johnson & Johnson will have 90 days to reply.
Withdrawal of Plaintiffs’ Causation Experts and the Evidentiary Record
The dispute arose after plaintiffs withdrew two physicians who were positioned to provide specific-causation opinions in the MDL’s bellwether cases: Dr. Daniel Clarke-Pearson and Dr. Judith Wolf. Johnson & Johnson argued that, during May admissibility hearings, the experts effectively conceded the absence of a reliable method to link talc exposure to a particular woman’s ovarian cancer. The defense contended that the withdrawal left the bellwether cases—and by extension the broader docket—without admissible proof on a required element, warranting dismissal. The defense is represented by Sills Cummis & Gross PC, according to court filings.
Judge Singh’s order draws on the hearing record to question whether the existing scientific tools can support individualized attribution in this context. The court highlighted testimony indicating uncertainty about how to rule in or rule out competing ovarian cancer risk factors for an individual patient. For example, the order cites Dr. Wolf’s inability to identify a way to exclude other risk factors for a particular claimant, and it states that Dr. Clarke-Pearson could not adequately justify why certain risk factors were ruled out in his analyses. That testimony, in the court’s view, raises a threshold concern: whether any expert could reliably evaluate multiple risk factors and determine which substantially contributed to a specific plaintiff’s disease.
Differential Etiology, Risk-Factor Interactions, and the “Substantial Factor” Debate
A central analytical issue in Judge Singh’s order concerns differential etiology—the method by which a clinician or expert attempts to identify the cause of an individual’s condition by considering and excluding alternative causes. The court focused on the practical implications of ovarian cancer’s multifactorial risk profile. If an expert cannot meaningfully distinguish among recognized risk factors—genetic predispositions, reproductive history, age, and other exposures—then the reliability of attributing causation to talc for a specific individual becomes difficult to establish. The order frames this as an admissibility and proof problem, not simply a question for the factfinder.
The plaintiffs argued that, even without determining whether risk factors act cumulatively, additively, or synergistically, an expert can still opine that talc use was a “substantial factor” in causing a particular woman’s ovarian cancer. Judge Singh rejected that premise as too disconnected from the mechanics of differential etiology. The order notes that these interaction models are distinct, and that the “type of effect” bears directly on an expert’s ability to reliably rule out other risk factors when concluding that talc substantially contributed to disease. The court also found that the withdrawn physicians did not adequately explain which interaction model they used when evaluating specific risk factors in the bellwether plaintiffs, undercutting the methodological clarity needed to support admissibility.
Procedural Next Steps and Implications for the Talc MDL
Judge Singh concluded that a show cause order is the appropriate mechanism to address the “uncertainty” over whether plaintiffs can meet their burden with admissible expert proof. The order positions the litigation at a juncture where the court may evaluate, in a coordinated way, whether claims can proceed absent reliable specific-causation opinions. While the ruling does not itself dismiss cases, it requires plaintiffs to articulate how they intend to prove specific causation and to identify the admissible expert support for that element. In a mass tort proceeding, that directive functions as an early merits screen tied directly to evidentiary standards.
The schedule set by the court provides a defined window for the parties to brief the issue: 120 days for plaintiffs’ submissions and 90 days for defendants’ responses. Johnson & Johnson has denied the allegations that its talc products cause ovarian cancer and has argued that decades of studies do not show a reliable causal link. Plaintiffs declined to comment following the order. The court’s approach underscores that the continued viability of large segments of the MDL may turn on whether plaintiffs can present experts who can reliably apply differential etiology to a complex set of competing risks—an issue that can shape case selection, settlement posture, and trial scheduling going forward.
